Strategies to circumvent humoral immunity to adeno-associated viral vectors
- 2 February 2015
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (6) , 845-855
Abstract
Introduction: Recent success in gene therapy of certain monogenic diseases in the clinic has infused enthusiasm into the continued development of recombinant adeno-associated viral (AAV) vectors as...Keywords
This publication has 111 references indexed in Scilit:
- Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueGene Therapy, 2012
- The AAV Vector Toolkit: Poised at the Clinical CrossroadsMolecular Therapy, 2012
- Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal ModelsMolecular Therapy, 2012
- A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8Molecular Therapy, 2011
- Engineering Biomaterial Systems to Enhance Viral Vector Gene DeliveryMolecular Therapy, 2011
- Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporineGene Therapy, 2011
- Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman PrimatesMolecular Therapy, 2011
- Antigen-specific immunotherapy of autoimmune and allergic diseasesCurrent Opinion in Immunology, 2010
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical TrialJournal of Cardiac Failure, 2009
- Rapamycin and mTOR kinase inhibitorsJournal of Chemical Biology, 2008